Clinical Trial Update: A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating trastuzumab in combination with TS-ONE and cisplatin as first-line therapy for HER2-positive advanced gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• TS-ONE
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: HER 2 Positive Advanced Gastric Cancer | Phase 2 | Status: COMPLETED